Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90095


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining irinotecan, leucovorin, and fluorouracil with ABX-EGF in treating patients who have metastatic colorectal cancer.

Study summary:

OBJECTIVES: - Determine progression-free survival of patients with metastatic colorectal cancer treated with monoclonal antibody ABX-EGF, irinotecan, leucovorin calcium, and fluorouracil. - Determine additional measures of clinical efficacy of this regimen in these patients. - Determine the safety of this regimen in these patients. - Determine the pharmacokinetics of monoclonal antibody ABX-EGF when administered with this regimen in these patients. - Determine the pharmacokinetics of irinotecan and its active metabolite SN-38 when administered with this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive monoclonal antibody ABX-EGF IV over 1 hour, irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV over 5 minutes on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed within 4 weeks, every 3 months for 1 year, and then every 6 months for 1 year. PROJECTED ACCRUAL: A total of 84 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically confirmed colorectal cancer - Metastatic disease - Must have been free of disease for at least 1 year if received prior adjuvant fluorouracil - Epidermal growth factor receptor (EGFR) over-expression by immunochemistry (staining 2+ or 3+ in at least 10% of tumor cells) - Unidimensionally measurable disease - No clinically significant ascites or pleural effusion - No known brain metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-1 Life expectancy - Not specified Hematopoietic - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - Bilirubin no greater than 2.0 mg/dL - AST and ALT no greater than 3 times upper limit of normal Renal - Creatinine no greater than 2.2 mg/dL Cardiovascular - LVEF at least 45% by MUGA - No myocardial infarction within the past year Other - HIV negative - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 1 month after study participation - No other malignancy within the past 5 years except basal cell carcinoma or carcinoma in situ of the cervix - No chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - See Disease Characteristics - No prior irinotecan Endocrine therapy - Not specified Radiotherapy - No prior or concurrent radiotherapy for colorectal cancer Surgery - Prior surgery for colorectal cancer allowed Other - At least 30 days since prior investigational drugs - No other prior therapy for colorectal cancer - No prior therapy for metastatic disease - No prior EGFR-targeting agents - No concurrent prochlorperazine during days 1-29 of each study course - No other concurrent EGFR-targeting agents - No other concurrent investigational drugs - No other concurrent therapy for colorectal cancer - No concurrent investigational supportive care therapy



Primary Contact:

Principal Investigator
Joel Randolph Hecht, MD
Jonsson Comprehensive Cancer Center

Backup Contact:


Location Contact:

Los Angeles, California 90095
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.